We Avoid RAAS Inhibitors in PD Patients with Residual Renal Function

Area of Science:

• Nephrology
• Cardiovascular Medicine

Background:

• Preserving residual renal function is crucial for improving mortality in peritoneal dialysis (PD) patients.
• Nephrotoxic agents should be avoided in PD patients, but the role of renin-angiotensin-aldosterone system (RAAS) inhibitors requires clarification.

Purpose of the Study:

• To evaluate the impact of RAAS inhibitors on preserving renal function and preventing dialysis failure in PD patients.
• To assess the effects of RAAS blockade on the peritoneal membrane.

Main Methods:

• This study reviews the current literature on RAAS inhibitors in PD patients.
• The review focuses on the effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on glomerular filtration rate and peritoneal membrane morphology.

Main Results:

• RAAS inhibitors are likely to preserve glomerular filtration rate, prolonging the time to anuria in PD patients.
• RAAS blockade may reduce morphologic changes in the peritoneal membrane, mitigating ultrafiltration failure.
• These effects may lead to improved mortality and delayed modality failure in PD patients.

Conclusions:

• Clinicians should continue RAAS inhibitors in PD patients to preserve renal function and prevent dialysis-related complications.
• Avoiding RAAS inhibitors in PD patients may negatively impact patient outcomes.
• Further research is warranted to fully elucidate the long-term benefits of RAAS blockade in PD.